Top 10 Update: Liquid Biopsy

Top 10 Update: Liquid Biopsy

Liquid biopsies, which ranked #4 in our Top 10 Medical Innovations of 2017,  identifies the presence of cancer by seeking signs of cell-free circulating tumor DNA (ctDNA) that is shed from a tumor into the bloodstream. The promise of these simple tests to one day replace the biopsy as the standard of care continues to gain steam. Last month, Dr. Nathan Pennell from Cleveland Clinic’s Taussig Cancer Institute spoke to OncLive about the progress, as well as the current challenge in getting liquid biopsies into the mainstream:
 
The technology “is here today and it’s already established, but the uses of it are much more limited than people understand. The validated uses are much more narrow. That may expand dependent on our identifying clinically proven uses for it as opposed to doing it because we can. There aren’t that many cases where being able to detect something in the blood has been validated to impact patient outcomes and survival. That’s what’s missing from a lot of the liquid biopsies.”
 
Read the entire article on OncLive.com
 

Get In Touch With Us